Celyad Oncology (Celyad Oncology) Retained Earnings : $-383.19 Mil (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Celyad Oncology Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Celyad Oncology's retained earnings for the quarter that ended in Jun. 2023 was $-383.19 Mil.

Celyad Oncology's quarterly retained earnings declined from Jun. 2022 ($-341.49 Mil) to Dec. 2022 ($-370.71 Mil) and declined from Dec. 2022 ($-370.71 Mil) to Jun. 2023 ($-383.19 Mil).

Celyad Oncology's annual retained earnings declined from Dec. 2020 ($-344.33 Mil) to Dec. 2021 ($-349.15 Mil) and declined from Dec. 2021 ($-349.15 Mil) to Dec. 2022 ($-370.71 Mil).

Celyad Oncology Retained Earnings Historical Data

The historical data trend for Celyad Oncology's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Retained Earnings Chart

Celyad Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Retained Earnings

Get a 7-Day Free Trial

-247.76

-82.69

-344.33

-349.15

-370.71

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Retained Earnings	Get a 7-Day Free Trial															-349.15	-348.65	-341.49	-370.71	-383.19

Celyad Oncology Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Celyad Oncology (OTCPK:CYADY) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Celyad Oncology (Celyad Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (OTCPK:CYADY) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

CYAD:Belgium

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.